Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something?

Literature DB >> 32016090

Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something?

Claudia Marchetti¹, Andrea Rosati^1,2, Giovanni Scambia^1,2, Anna Fagotti^1,2.

Abstract

Entities: Chemical Disease

Year: 2019 PMID： 32016090 PMCID： PMC6976449 DOI： 10.21037/atm.2019.12.94

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

× No keyword cloud information.

11 in total

1. Cancer statistics, 2018.

Authors: Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal: CA Cancer J Clin Date: 2018-01-04 Impact factor: 508.702

2. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Authors: Antonio González-Martín; Bhavana Pothuri; Ignace Vergote; René DePont Christensen; Whitney Graybill; Mansoor R Mirza; Colleen McCormick; Domenica Lorusso; Paul Hoskins; Gilles Freyer; Klaus Baumann; Kris Jardon; Andrés Redondo; Richard G Moore; Christof Vulsteke; Roisin E O'Cearbhaill; Bente Lund; Floor Backes; Pilar Barretina-Ginesta; Ashley F Haggerty; Maria J Rubio-Pérez; Mark S Shahin; Giorgia Mangili; William H Bradley; Ilan Bruchim; Kaiming Sun; Izabela A Malinowska; Yong Li; Divya Gupta; Bradley J Monk
Journal: N Engl J Med Date: 2019-09-28 Impact factor: 91.245

3. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Authors: Eric Pujade-Lauraine; Jonathan A Ledermann; Frédéric Selle; Val Gebski; Richard T Penson; Amit M Oza; Jacob Korach; Tomasz Huzarski; Andrés Poveda; Sandro Pignata; Michael Friedlander; Nicoletta Colombo; Philipp Harter; Keiichi Fujiwara; Isabelle Ray-Coquard; Susana Banerjee; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Patricia Pautier
Journal: Lancet Oncol Date: 2017-07-25 Impact factor: 41.316

4. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.

Authors: Allison Gockley; Alexander Melamed; Angel Cronin; Michael A Bookman; Robert A Burger; Mihaela C Cristae; Jennifer J Griggs; Gina Mantia-Smaldone; Ursula A Matulonis; Larissa A Meyer; Joyce Niland; David M O'Malley; Alexi A Wright
Journal: Am J Obstet Gynecol Date: 2019-06-14 Impact factor: 8.661

5. BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.

Authors: Claudia Marchetti; Rossella De Leo; Angela Musella; Marco D'Indinosante; Ettore Capoluongo; Angelo Minucci; Pierluigi Benedetti Panici; Giovanni Scambia; Anna Fagotti
Journal: Ann Surg Oncol Date: 2018-08-20 Impact factor: 5.344

6. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Authors: Mansoor R Mirza; Bradley J Monk; Jørn Herrstedt; Amit M Oza; Sven Mahner; Andrés Redondo; Michel Fabbro; Jonathan A Ledermann; Domenica Lorusso; Ignace Vergote; Noa E Ben-Baruch; Christian Marth; Radosław Mądry; René D Christensen; Jonathan S Berek; Anne Dørum; Anna V Tinker; Andreas du Bois; Antonio González-Martín; Philippe Follana; Benedict Benigno; Per Rosenberg; Lucy Gilbert; Bobbie J Rimel; Joseph Buscema; John P Balser; Shefali Agarwal; Ursula A Matulonis
Journal: N Engl J Med Date: 2016-10-07 Impact factor: 91.245

7. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Authors: Kathleen Moore; Nicoletta Colombo; Giovanni Scambia; Byoung-Gie Kim; Ana Oaknin; Michael Friedlander; Alla Lisyanskaya; Anne Floquet; Alexandra Leary; Gabe S Sonke; Charlie Gourley; Susana Banerjee; Amit Oza; Antonio González-Martín; Carol Aghajanian; William Bradley; Cara Mathews; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Paul DiSilvestro
Journal: N Engl J Med Date: 2018-10-21 Impact factor: 91.245

8. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors: Robert L Coleman; Amit M Oza; Domenica Lorusso; Carol Aghajanian; Ana Oaknin; Andrew Dean; Nicoletta Colombo; Johanne I Weberpals; Andrew Clamp; Giovanni Scambia; Alexandra Leary; Robert W Holloway; Margarita Amenedo Gancedo; Peter C Fong; Jeffrey C Goh; David M O'Malley; Deborah K Armstrong; Jesus Garcia-Donas; Elizabeth M Swisher; Anne Floquet; Gottfried E Konecny; Iain A McNeish; Clare L Scott; Terri Cameron; Lara Maloney; Jeff Isaacson; Sandra Goble; Caroline Grace; Thomas C Harding; Mitch Raponi; James Sun; Kevin K Lin; Heidi Giordano; Jonathan A Ledermann
Journal: Lancet Date: 2017-09-12 Impact factor: 79.321

Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something?

1. Cancer statistics, 2018.

2. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

3. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

4. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.

5. BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.

6. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

7. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

8. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

9. The role of secondary surgery in recurrent ovarian cancer.

10. Treatment of recurrent epithelial ovarian cancer.

Review 1. Surgery vs. chemotherapy for ovarian cancer recurrence: what is the best treatment option.

Review 2. Role of ultrasound in the detection of recurrent ovarian cancer: a review of the literature.

3. Tanshinone IIA suppresses ovarian cancer growth through inhibiting malignant properties and angiogenesis.

4. Natural compound Tan-I enhances the efficacy of Paclitaxel chemotherapy in ovarian cancer.